PFE$25.87
$25.85
Chart
Performance
Key Stats
AI PFE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPfizer demonstrates solid fundamental strength with a high dividend yield and consistent EPS surprises. While recent performance has been mixed and technical indicators suggest some short-term caution, its long-term outlook remains positive, especially considering its role in essential healthcare sectors.
Thematic
Pfizer operates in the essential healthcare and biopharmaceutical sector, benefiting from long-term demographic trends and ongoing demand for medicines and vaccines. However, it faces thematic headwinds related to pricing pressures and intense competition.
Fundamental
Pfizer exhibits strong profitability and a robust balance sheet. Consistent positive EPS surprises and a high dividend yield are attractive. Revenue and net income have shown volatility, partly due to the tapering of COVID-19 related products, but underlying operational performance is solid.
Technical
Pfizer's stock price has shown mixed performance, with recent gains offset by earlier declines. While it's trading above key long-term moving averages, short-term indicators suggest consolidation or potential for a slight pullback.
| Factor | Score |
|---|---|
| Global Health & Pharmaceuticals | 85 |
| Biotechnology Innovation | 75 |
| Healthcare Cost & Pricing Pressures | 40 |
| Competitive Landscape | 60 |
| Emerging Markets Growth | 70 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 80 |
| Growth | 50 |
| Balance Sheet Health | 70 |
| Cash Flow | 78 |
| Dividend | 95 |
| Earnings Consistency | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Analysis | 55 |
| Support and Resistance | 65 |
| Market Sentiment (Technical Indicators) | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong EPS Beat
The company has consistently beaten earnings per share (EPS) estimates, with the latest quarter reporting an EPS of $0.92 against an estimate of $0.66, a significant positive surprise of 38.83%.
Improving Debt Situation
Debt has decreased from $70.8 billion in Q4 2023 to $63.6 billion in Q4 2024, while cash and cash equivalents increased to $1.04 billion, indicating improving leverage and liquidity.
Bearish Points (7)
Recent Underperformance
The stock has experienced a -13.33% decline over the past year and a -1.31% year-to-date, suggesting potential headwinds or a market re-evaluation.
Quarterly Valuation Volatility
Quarterly P/E ratios show significant fluctuations, with Q1 2025 at 47.6 and Q4 2024 at 355.1, indicating potential valuation concerns and unpredictability.
Calendar
July 2025
25
Ex-Dividend Date
August 2025
5
Next Earnings Date
H: $0.62
A: $0.57
L: $0.47
H: 14.16B
A: 13.53B
L: 13.10B
September 2025
2
Next Dividend Date
Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Seasonals
Price Target
29.23 USD
The 39 analysts offering 1 year price forecasts for PFE have a max estimate of 41.49 and a min estimate of 23.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Co-developer of Comirnaty (COVID-19 vaccine) with Pfizer, demonstrating a critical and revenue-generating partnership.
Weight: 95
Direct competitor in mRNA vaccine technology and a major player in the COVID-19 vaccine market, often compared to Pfizer's vaccine efforts.
Weight: 92
Major pharmaceutical competitor across various therapeutic areas including oncology (e.g., Keytruda vs. Pfizer's oncology pipeline), vaccines, and infectious diseases.
Weight: 90
Significant pharmaceutical competitor, particularly in high-growth areas like diabetes, obesity, and oncology, often vying for market leadership.